Cabaletta Bio, Inc. Common Stock
CABACabaletta Bio, Inc. is a biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. Its platform aims to selectively target and deplete pathogenic B cells responsible for autoimmune conditions, utilizing proprietary technologies to improve the specificity and safety of treatments.
Company News
Cabaletta Bio announces positive clinical data for its rese-cel therapy in patients with myositis, lupus, and scleroderma, with most patients achieving clinically meaningful responses while off immunomodulators and steroids. The company plans to initiate registrational trials and engage with the FDA on regulatory pathways.
Cabaletta Bio announced plans to submit a Biologics License Application (BLA) for its rese-cel therapy in myositis by 2027, following recent alignment with the FDA on registrational cohorts for the RESET-Myositis trial. The company also received Regenerative Medicine Advanced Therapy (RMAT) designation for rese-cel in myositis.
Cabaletta Bio, a clinical-stage biotechnology company, announced that it will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on February 5, 2025. The company is focused on developing curative targeted cell therapies for autoimmune diseases.
US stock futures are pointing to a higher open on Friday as investors look to end November on a positive note. Analysts suggest that December has historically been a strong month for markets, with only one instance of it being the worst month in the last 95 years.
Cabaletta Bio, a clinical-stage biotechnology company, announced its participation in several investor conferences in September 2024, including the Morgan Stanley, Wells Fargo, H.C. Wainwright, and Cantor Fitzgerald conferences.
